FluidAI Receives FDA Approval to Market Post-Surgery Monitor in the U.S.

FluidAI Medical's US Expansion and Series B Plans

Kitchener-Waterloo healthtech startup FluidAI Medical has achieved a significant milestone by receiving FDA approval for its device, the Origin, which predicts post-surgery complications. This clearance as a Class 2 medical device allows FluidAI to tap into the US healthcare market, deemed the largest in the world.

In a recent interview, CEO and co-founder Youssef Helwa expressed that this achievement is pivotal for the company and highlights five years of development, including extensive studies and trials across four continents. The approval paves the way for FluidAI to initiate a Series B funding round focused on expanding into the US market, although Helwa withheld specific funding targets.

Founded in 2014 as Nerv Technology, FluidAI specializes in data-driven surgical recovery, specifically concentrating on predicting complications after general and gastrointestinal surgeries. The startup collaborates with over 35 medical centers globally, including well-known institutions like Cleveland Clinic and Toronto’s University Health Network. To date, FluidAI has raised over $20 million, most recently securing $15 million in a Series A round in 2023.

The Origin device is an innovative real-time surgical drain monitor that assesses the biochemical composition of patient fluids to identify potential complications early. It integrates into existing surgical drains and utilizes sensors and machine learning to monitor parameters like pH, electrical conductivity, and temperature. This proactive monitoring aims to catch potentially life-threatening issues, specifically anastomotic leaks, before they manifest clinically.

FluidAI has already begun selling the Origin device in Canada and the Middle East, with Helwa estimating that nearly 3.5 million patients in the US could benefit from the technology. In addition to Origin, FluidAI offers Stream Care, a sophisticated software platform that predicts post-surgery complication risks using patients' electronic health records and data from devices like Origin. The AI-driven Stream Care not only generates clinical documentation but also streamlines coding and eases administrative workloads. Additionally, it aids patient engagement and education through various innovative tools, including a conversational assistant and symptom monitoring.

Helwa confirmed that FluidAI possesses adequate manufacturing capacity in Kitchener-Waterloo to fulfill immediate demands and early-stage US expansion needs. Although the startup has faced challenges from US tariffs, Helwa believes they have managed the impact better than other sectors by collaborating with partners to mitigate costs. As FluidAI prepares for broader operations in the US, establishing a local office to better support clients, partners, and patients is part of the plan, though he is uncertain if a manufacturing facility will be necessary.

FluidAI aspires to cross a notable threshold by assisting 100,000 operations, with ambitions to expand into a more diverse range of surgical procedures and to introduce additional products in the future. This ambitious growth trajectory is reflective of FluidAI's commitment to enhancing surgical recovery through innovative technology and data-driven solutions, positioning the company as a significant player in the healthtech landscape.